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Abstract
Background The impact of dose and simultaneous use of acid-reducing agents (ARAs) on the effectiveness of vemurafenib is
unknown.
Objectives To determine the association between progression of metastatic BRAF V600 mutated melanoma and (1) dose reduc-
tions of vemurafenib and (2) simultaneous use of vemurafenib and ARAs.
Patient and Methods A retrospective cohort study of 112 first-line vemurafenib users for melanoma was conducted
(March 2012–March 2016), using electronic patient records and pharmacy dispensing records of a Dutch academic hospital.
Cox regression analysis was used to estimate the risk of progression with full-dose (n = 64) versus reduced-dose vemurafenib
(n = 48) and with simultaneous use of vemurafenib and ARAs (n = 35) versus vemurafenib alone (n = 77). Analyses were
adjusted for age and sex.
Results In total, disease progression occurred in 55% of treated patients on vemurafenib, with a median progression-free survival
of 6.0 (95% confidence interval [CI] 5.0–6.9) months. Compared to patients on vemurafenib alone, there was no increased risk of
progression among patients requiring vemurafenib at a reduced dose or among patients receiving simultaneous therapy with
vemurafenib and ARAs. In addition, there was no increased risk of progression among patients who used reduced-dose
vemurafenib and ARAs versus those receiving full-dose vemurafenib as sole therapy. However, a tendency for progression
was observed among patients who used full-dose vemurafenib and ARAs versus full-dose vemurafenib alone (adjusted hazard
ratio [HRa] 2.37; 95% CI 0.97–5.76), which became statistically significant in a sensitivity analysis (HRa 4.56; 95% CI 1.51–
13.75).
Conclusions There was no association between the use of vemurafenib in a reduced dose or the simultaneous use of vemurafenib
and ARAs and the risk of progression. In addition, there was no association between the simultaneous use of vemurafenib in a
reduced dose and ARAs and the risk of progression. However, patients tolerating full-dose vemurafenib simultaneously with
ARAs might have an increased risk of progression. This finding requires prospective validation.
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1 Introduction
Until recently, the prognosis for melanoma patients with dis-
tant metastases was poor, with 1-year survival rates ranging
from 33 to 62% among patients with stage IV melanoma [1].
Mutations in the BRAF gene can be detected in approximately
40–60% of metastatic melanoma cases and lead to the consti-
tutive activation of downstream MAP kinase/ERK-signaling,
resulting in cell proliferation and survival [2]. Vemurafenib is
a potent, selective inhibitor of the mutated BRAF V600 pro-
tein kinase [2]. In the BRIM-3 trial, which evaluated
vemurafenib as first-line treatment of melanoma with BRAF
V600 mutations, progression-free survival (PFS) was signifi-
cantly longer for patients receiving vemurafenib than for those
on dacarbazine, with a median PFS of 6.9 versus 1.6 months,
respectively (hazard ratio [HR] 0.38; 95% confidence interval
[CI] 0.32–0.46; p < 0.001) [2, 3]. Moreover, this improvement
was also reflected in a significantly longer median overall
survival (OS) of 13.6 months for vemurafenib as compared
to 9.7 months for dacarbazine (HR 0.70; 95% CI 0.57–0.87;
p = 0.0008) [3]. This trial resulted in the approval of
vemurafenib as first-line treatment of metastatic BRAF V600
mutatedmelanoma by the U.S. Food andDrugAdministration
in August 2011, followed by the approval by the European
Medicines Agency in December 2011.
Currently, vemurafenib is not dosed on an individual basis,
and no dose increments are allowed. The standard starting
dose is 960 mg orally twice daily, which may be reduced in
case of toxicity or frailty. After oral intake, the bioavailability
of vemurafenib is assumed to be modest [4]. Vemurafenib
shows dose-proportional pharmacokinetics from a dose of
240 mg twice daily to 960 mg twice daily [5–7]. Due to
the large intra- and interpatient pharmacokinetic variability
of vemurafenib, the recommended fixed starting dose will
lead to substantial differences in vemurafenib exposure and
may thereby result in either under- or overexposure [7–9].
Both are likely to affect treatment outcome, since an expo-
sure–response relationship has been shown for vemurafenib
[5, 9–11]. Patients tolerating full-dose vemurafenib may be
the subgroup underexposed to vemurafenib, while patients
experiencing toxicities due1 to vemurafenib may reflect a
subgroup of patients who are overexposed, and thus in need
of dose reduction.
Vemurafenib absorption can be decreased with simulta-
neous use of acid-reducing agents (ARAs), since the solubility
of vemurafenib drops when gastric pH is > 2.8 [5, 12]. Data
from two American healthcare databases showed that the
prevalence of ARA use ranged from 14 to 29% among mela-
noma patients [12]. Simultaneous use of proton pump inhibi-
tors (PPIs) was shown to reduce the area under the concentra-
tion–time curve of other tyrosine kinase inhibitors by 46 to
61% [13–15]. Patients using vemurafenib simultaneously
with ARAs may therefore be at risk of underexposure to
vemurafenib due to the potential interaction between ARAs
and vemurafenib [12, 16].
It is currently unknown whether the use of reduced-dose
vemurafenib positively affects treatment outcomes of
vemurafenib and whether the use of ARAs negatively affects
treatment outcomes of vemurafenib. The objectives of this
study were, therefore, to determine the association between
the progression of metastatic BRAF V600 mutated melanoma
and (1) dose reductions of vemurafenib and (2) simultaneous
use of ARAs.
2 Materials and Methods
2.1 Data Source
The treatment of patients with metastatic melanoma in the
Netherlands is centralized in 14 designated medical centers.
Requirements of the national reimbursement system are such
that vemurafenib prescriptions can only be dispensed at the
pharmacy that is affiliated to the respectivemelanomamedical
center, which ensures a perfect capture of vemurafenib expo-
sure. Data for this study were obtained from both the pharma-
cy dispensing data and the electronic patient records of an
academic hospital in the Netherlands, which were linked at
an individual patient level. The pharmacy dispensing data
included information on (co-)medication, such as ARAs,
cobimetinib, potent inductors or inhibitors of cytochrome
P450 enzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp),
the prescribed dose of vemurafenib, and the starting date of
vemurafenib treatment. The electronic patient records
contained information on the date and reason for vemurafenib
discontinuation (disease progression, toxicity, hospital admis-
sion, death, switch to different lines of treatment, and/or sur-
gical interventions). All data entries were checked by
independent researchers.
Key Points
This study investigated the impact of dose and 
simultaneous use of acid reducing agents (ARAs) 
on the effectiveness of vemurafenib.
We found no association between the use of vemurafenib 
in a reduced dose or the simultaneous use of vemurafenib 
and ARAs and the risk of progression.
However, patients tolerating full-dose vemurafenib
simultaneously with ARAs might have an increased
risk of progression
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2.2 Study Population
With the approval of the Research Ethics Board (Arnhem/
Nijmegen), we conducted a retrospective cohort study and
reviewed pharmacy dispensing data to identify patients who
had started vemurafenib as first-line treatment for metastatic
BRAF V600 mutated melanoma between 17 March 2012 and
17March 2016. The first vemurafenib dispensing by the phar-
macy was defined as the start of follow-up (index date). A
total of 115 patients were selected based on the pharmacy
dispensing data, and we included all patients aged 18+ years
at the start of follow-up who had least one vemurafenib pre-
scription dispensed. Two patients were excluded because their
melanoma was not BRAF V600 mutated after revision by our
molecular biology laboratory. One patient was excluded be-
cause the electronic patient record was lacking information on
the safety and effectiveness of vemurafenib (Fig. 1). No other
exclusion criteria were defined in order to reflect a ‘real-life’
retrospective cohort.
2.3 Exposure
The follow-up was divided into 7-day intervals. Patients were
followed up to death, censoring, or disease progression (the
outcome of interest) as recorded in the electronic patient files,
whichever came first. Reasons for censoring included
switching to different lines of therapy before disease progres-
sion occurred, toxicity, surgical interventions, loss to follow-
up, and the end of the study period.
At the start of each interval, the most recently dispensed
dose of vemurafenib was determined using the pharmacy dis-
pensing data. These data were then compared to the dispensed
dose of the penultimate vemurafenib dispensed to assess
whether a dose change had taken place. person-time was di-
vided into three categories (‘before dose reduction;’ ‘after
dose reduction;’ ‘no dose reduction’) since it was hypothe-
sized that patients experiencing toxicities while using full-
dose vemurafenib could be overexposed and therefore in need
of a dose reduction. When a dose reduction did occur, time
was separated into two different exposure categories: ‘before
dose reduction’ and ‘after dose reduction’. Patients using full-
dose vemurafenib during their entire treatment were classified
as ‘no dose reduction’ (960 mg twice daily).
Furthermore, prior to the start of each interval, exposure to
ARAs (PPIs, H2 receptor antagonists, or antacids) was deter-
mined using the pharmacy dispensing data. ARAs were iden-
tified by the following Anatomical Therapeutic Chemical
(ATC) codes: A02BC, A02BA, and A02A [17]. A current
ARA user was defined as someone who had his most recent
ARA dispensed within the 30 days prior to the start of an
interval, while past ARA users had received their most recent
ARA dispensed > 30 days previously.
2.4 Outcomes
The outcome of interest was PFS in patients with metastatic
BRAF V600 mutated melanoma on first-line vemurafenib.
Progression was either assessed radiologically or clinically
by the treating physician. PFS was defined as the time from
dispensing of first vemurafenib prescription until the occur-
rence of new lesions or the progression of existing lesions.
2.5 Potential Confounders
Age and sex were considered to be potential confounders and
were incorporated as covariates into the analyses. Sex was
determined at baseline, and age was determined time
dependently.
2.6 Co-Medication
The influence of concomitant administration of potent induc-
tors or inhibitors of CYP3A4 and P-gp was assessed because
vemurafenib is mainly metabolized by CYP3A4 and is a sub-
strate of P-gp.
2.7 Statistical Analysis
Regression analysis with the Cox proportional hazards
model (PHREG procedure, SAS version 9.4; SAS
Institute, Cary, NC, USA) was used to estimate disease
progression among (1) full-dose vemurafenib users (n =
64) versus reduced-dose vemurafenib users (n = 48); (2)
simultaneous ARA use (n = 35) versus no ARA use (n =
77); (3) the combination of both exposure groups.
Multivariate analysis was used to adjust for age and sex.
PFS was estimated using the Kaplan–Meier method.
First-line vemurafenib users
n=115
First-line vemurafenib users
n=112
First-line vemurafenib users
n=113
No BRAF V600 mutation
n=2
Included
Excluded
Incomplete electronic patient record
n=1
Fig. 1 Flow chart of the study population according to entry criteria
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2.8 Sensitivity Analysis
A sensitivity analysis was performed using only pharmacy
dispensing data to determine the discontinuation date of
vemurafenib exposure. This discontinuation date was added
to the previously defined censoring events. Discontinuation of
vemurafenib was defined as the estimated end date of the
dispensing based on the total number of dispensed tablets
and the number of prescribed tablets per day. In the case of
no new dispensing during the 28 days after the estimated end
data, patients were censored at the estimated end date of the
dispensing. This maximum tolerated gap period of
vemurafenib was similar to the maximum discontinuation pe-
riod in clinical trials. In another sensitivity analysis, the time-
window of the time since the most recent ARA prescription
(i.e., current use) was varied to 15 or 60 days, respectively,
prior to the start of an interval. ARAs are likely to be dis-
pensed for either a short period of time or for long period of
time, but they may also be used by patients on an ‘as needed
basis’.
3 Results
3.1 Study Population at Baseline
Among the 112 patients fulfilling the inclusion criteria
(Fig. 1), 45 were female (40.2%) and the median age at
index date was 60 (range 26–81) years. In total, 64 patients
were using full-dose vemurafenib during the entire study
period, and 35 patients were using ARAs. The ARAs used
by the patients in this study were the PPIs esomeprazole,
omeprazole, and pantoprazole, the H2-receptor antagonist
ranitidine, and the antacids magnesium hydroxide and or-
dinary salt combinations. Further, four patients were treat-
ed with vemurafenib in combination with cobimetinib. Of
those four patients, two were using full-dose vemurafenib
during the entire study period and two were using ARAs.
None of the patients treated with vemurafenib concomi-
tantly used strong CYP3A4 or P-gp inducers or inhibitors.
3.2 Study Population at Outcome
The patient outcome characteristics are shown in Table 1. In
total, 62 patients (55.4%) showed disease progression on first-
line vemurafenib. Censoring occurred in 50 patients (44.6%),
mainly due to switching to immunotherapy before disease
progression occurred (20.5%), toxicity (12.5%), surgical re-
section (3.6%), or loss to follow-up (2.7%). Six patients
(5.4%) were still on vemurafenib at the end of the follow-up
period. The median PFS was 6.0 (95% CI 5.0–6.9) months.
3.3 Dose Reductions of Vemurafenib and/or
Simultaneous Use of ARAs and Risk of Disease
Progression
Patients using vemurafenib in a reduced dose had no increased
risk of disease progression as compared to full-dose
vemurafenib users (adjusted HR [HRa] 1.12; 95% CI 0.64–
1.61) (Table 2). Vemurafenib users who had used ARAs within
the past 30 days had no increased risk of disease progression
(HRa 1.23; 95% CI 0.53–2.85) as compared to vemurafenib
users not using ARAs. There was no increased risk of progres-
sion among patients who used reduced-dose vemurafenib and
ARAs versus those on full-dose vemurafenib alone (HRa 1.00;
95% CI 0.45–2.20). However, a tendency for disease progres-
sion was observed among patients who had used full-dose
vemurafenib and ARAs at the same time versus those who used
full-dose vemurafenib alone (HRa 2.37; 95% CI 0.97–5.76).
3.4 Sensitivity Analysis
In a sensitivity analysis in which we used pharmacy dispens-
ing data to determine the discontinuation date of vemurafenib
exposure, only 41 patients showed disease progression
(Table 3). In this sensitivity analysis, there was no association
between full-dose vemurafenib use versus reduced-dose
vemurafenib use and disease progression. In addition, there
was no increased risk of progression among patients who used
reduced-dose vemurafenib and ARAs versus those on full-
dose vemurafenib alone (HRa 0.99; 95% CI 0.35–2.75).
However, a statistically significant 4.6-fold increased risk of
disease progression was found among patients who had used
full-dose vemurafenib and ARAs at the same time versus
those who had used full-dose vemurafenib alone (HRa 4.56;
95% CI 1.51–13.75). In a second sensitivity analysis, current
ARA use was determined by varying the time since the most
recent ARA prescription to 15 or 60 days, respectively
(Table 4). For both time-windows, we found no associations
Table 1 Outcome characteristics of metastatic BRAF V600
mutated melanoma patients (N = 112)
Outcome characteristics N (%)
Progression 62 (55.4)
Female 28 (45.2)
Male 34 (54.8)
Censoring 50 (44.6)
Switch to different lines of therapy 23 (20.5)
Toxicity 14 (12.5)
End of follow-up period 6 (5.4)
Surgical intervention 4 (3.6)
Lost to follow-up 3 (2.7)
Death 0 (0)
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for current and past ARA use with disease progression as
compared to no ARA use.
4 Discussion
In the present study we found no increased risk of the progres-
sion of metastatic BRAF V600 mutated melanoma after dose
reductions of vemurafenib, or with simultaneous use of
vemurafenib and ARAs, versus vemurafenib alone. In addi-
tion, there was no increased risk of progression among pa-
tients who used reduced-dose vemurafenib and ARAs versus
those who used full-dose vemurafenib alone. However, a ten-
dency for disease progression was observed among patients
who used full-dose vemurafenib and ARAs at the same time
versus those on full-dose vemurafenib alone when determin-
ing exposure to vemurafenib using electronic patient records.
The risk for disease progression became significantly elevated
Table 2 Dose reductions of vemurafenib and/or simultaneous use of acid reducing agents and risk of disease progression of metastatic BRAF V600
mutated melanoma
Vemurafenib exposure Events (n = 62) Incidence rate
(events /10 person-years)
Unadjusted HR
(95% CI)
Age-sex adjusted
HR (95% CI)
By dose reduction
No dose reduction (960 mg BID)a 31 18.5 Reference Reference
Reduced doseb 31 18.9 1.00 (0.59–1.67) 1.12 (0.64–1.61)
By simultaneous ARA use
No ARA exposure 40 14.6 Reference Reference
Current ARA usec 9 20.4 1.24 (0.54–2.87) 1.23 (0.53–2.85)
Past ARA used 13 16.4 1.05 (0.54–2.03) 1.03 (0.53–2.00)
By simultaneous ARA use and dose reductionse
No dose reduction (960 mg BID)a, no ARA use 19 14.6 Reference Reference
No dose reduction (960 mg BID)a, ARA use 12 32.5 2.49 (1.03–6.01)* 2.37 (0.97–5.76)
Reduced doseb, no ARA use 21 21.3 1.48 (0.77–2.85) 1.40 (0.72–2.73)
Reduced doseb, ARA use 10 15.2 1.02 (0.46–2.26) 1.00 (0.45–2.20)
ARA Acid-reducing agent, BID twice daily, CI confidence interval, HR hazard ratio
*Statistically significant at p < 0.05
a Full-dose (960 mg BID): person-time of patients using 960 mg vemurafenib BID during entire follow-up period
b Reduced dose: person-time of patients using vemurafenib in a reduced dose after the dose reduction
c Current ARA use: most recent ARA prescription within 30 days before start of an interval
d Past ARA use: most recent ARA prescription at more than 30 days before start of an interval
e Before dose reduction person-time of patients using 960 mg vemurafenib BID not shown due to zero number of events
Table 3 Sensitivity analysis: dose reductions of vemurafenib and simultaneous use of acid-reducing agents and risk of disease progression of
metastatic BRAF V600 mutated melanoma
Vemurafenib exposure Events (n = 41) Incidence rate
(events /10 person-years)
Unadjusted HR
(95% CI)
Age-sex adjusted
HR (95% CI)
By simultaneous ARA use and dose reductionsa
No dose reduction (960 mg BID)b, no ARA use 14 12.7 Reference Reference
No dose reduction (960 mg BID)b, ARA use 10 30.8 4.83 (1.61–14.46)* 4.56 (1.51–13.75)*
Reduced dosec, no ARA use 11 15.5 1.42 (0.60–3.32) 1.22 (0.50–2.93)
Reduced dosec, ARA use 6 10.9 1.00 (0.36–2.75) 0.99 (0.35–2.75)
Exposure was calculated from pharmacy dispensing data only
ARA Acid-reducing agent, BID twice daily, CI confidence interval, HR hazard ratio
*Statistically significant at p < 0.05
a Before dose reduction person-time of patients using 960 mg vemurafenib BID not shown due to zero number of events
b Full-dose (960 mg BID): person-time of patients using 960 mg vemurafenib BID during the entire follow-up period
c Reduced dose: person-time of patients using vemurafenib in a reduced dose after the dose reduction
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to almost fivefold in a sensitivity analysis in which a discon-
tinuation date of vemurafenib (based on pharmacy dispensing
records) was added as a censoring event.
To the best of our knowledge, this is the first study to
investigate the influence of vemurafenib dose reductions, si-
multaneous use of vemurafenib and ARA, and full-dose
vemurafenib use simultaneously with ARAs on the risk of
disease progression in melanoma patients [12, 16]. It is pre-
sumed that co-treatment with ARAs will reduce vemurafenib
plasma concentrations. Vemurafenib has only limited solubil-
ity at pH 1 (e.g., the physiologic pH of the stomach), but has
even less solubility at pH > 2.8 (i.e., the pKa value of
vemurafenib) [5]. Since the use of ARAs may increase the
gastric pH to ≥ 4, it is possible that an ARA–vemurafenib
interaction occurs that affects vemurafenib uptake [5, 12].
Several previous studies have shown results in line with
our findings. Our median PFS was 6.0 (95% CI 5.1–6.9)
months, which is comparable to the PFS reported in the study
of McArthur et al. (6.9 months) and Kramkimel et al.
(5.0 months) [3, 11]. Furthermore, we found dose reductions
in 43% of the patients using vemurafenib, which is compara-
ble to 38–50% of the patients requiring a dose reduction in
other studies [2, 9, 18]. In addition, we identified a complete
discontinuation of vemurafenib due to toxicity in 13% of our
patients, which is comparable to the 12% identified in the
study by Kramkimel et al. [11]. These results suggest that
our population of ‘real-life’ melanoma patients was compara-
ble to earlier studied melanoma patient populations.
Other studies have reported a relationship between
vemurafenib plasma concentrations and treatment outcome
(i.e., toxicity and effectiveness), identifying a minimal target
steady state concentration of 42μg/mL [9, 11]. High inter- and
intrapatient variability at steady-state pharmacokinetics was
observed, also when focusing only on the patients taking
full-dose vemurafenib [9, 18]. In addition, patients treated
with a reduced dose of vemurafenib due to adverse events
had nearly similar plasma concentrations as patients who tol-
erated full-dose vemurafenib [9]. These observations indicate
that patients requiring dose reductions might be overexposed
when taking full-dose vemurafenib [9]. The effect of simulta-
neous ARA use on treatment outcome will likely be most
pronounced in patients with plasma concentrations close to
the target concentration of 42 μg/mL during the entire treat-
ment period, i.e., the group of patients tolerating full-dose
vemurafenib [9]. Therefore, patients tolerating full-dose
vemurafenib while simultaneously using ARAs may be of
particular risk of early progression due to vemurafenib plasma
concentrations below the target level, a possibility which is
supported by our results. Modifying the vemurafenib dose
based on plasma concentrations could be an elegant and pa-
tient friendly way to optimize vemurafenib therapy for indi-
vidual patients [18]. Unfortunately, data on vemurafenib plas-
ma concentrations were not collected for the patients includedTa
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in our cohort; such data could be the starting point for future
studies.
Information regarding the exposure–response relationship
of vemurafenib used in combination with cobimetinib is lack-
ing. The target might be equal or below the earlier identified
target for monotherapy with vemurafenib of 42 μg/mL, since
efficacy was demonstrated with the same dose as used in
monotherapy and no interaction between both drugs was iden-
tified [19]. It is therefore yet unknown if the increased risk of
progression is still present in a population of metastatic BRAF
V600 patients who are treated with vemurafenib and
cobimetinib and simultaneously using ARAs.
It is important to note the shortcomings of this retrospective
database study. True causality cannot be provided with this
study. Further, the simultaneous use of vemurafenib with
ARAs was difficult to assess. ARAs could be obtained at
multiple pharmacies and are available over the counter (with-
out dispensing), making an accurate estimation of co-use chal-
lenging. The electronic network linkage of pharmacies
allowed us to use drug dispensing data from other healthcare
providers; however, completeness of the pharmacy dispensing
data could not be guaranteed. This potential misclassification
of exposure may have resulted in an underestimation of the
effect. Additionally, it is likely that our observed associations
are not without residual confounding. Factors that could not
be retrieved from the medical records of the patients, and thus
were not adjusted for, were food intake (e.g., use of
vemurafenib with or without food), the use of food supple-
ments (e.g., grapefruit juice), and herbal supplements (e.g., St.
John’s wort) [4, 16, 20]. Lastly, confounding by disease se-
verity might be present. Patients with brain metastases are
often treated with the CYP3A4 inductor dexamethasone,
which might result in a lower exposure of vemurafenib. We
recommend future prospective studies to correct for factors
such as food and/or herbal intake, disease severity, and simul-
taneous use of dexamethasone.
Notwithstanding, our study has a number of important
strengths. First of all, we were able to include a relatively large
group of BRAF V600 mutated metastatic melanoma patients
using vemurafenib as first-line treatment. Moreover, we ap-
plied no other exclusion criteria, thereby providing a represen-
tative sample of ‘real-life’ melanoma patients who can there-
fore be extrapolated to the general population of melanoma
patients. Second, we were able to obtain information from
both the pharmacy dispensing data and the electronic patient
record. The data collected is assumed to be reliable, since all
data entries were checked independently by researchers.
Moreover, due to different data sources we were able to inves-
tigate the presence of potential misclassification of
vemurafenib exposure. In the sensitivity analyses using only
pharmacy dispensing data to determine a discontinuation date
of vemurafenib, we found a significant risk of progression in
patients using full-dose vemurafenib and ARAs at the same
time versus those using full-dose vemurafenib alone. The
presence of non-differential misclassification of exposure re-
sults in an effect towards the null [21], which might explain
the difference in the results between using the pharmacy data
and the electronic patient records data (HRa 4.56; 95% CI
1.51–13.75 and HRa 2.37; 95% CI 0.97–5.76, respectively).
Third, in order to control for confounding by indication, we
only included patients using first-line vemurafenib. It has been
found that pretreated patients have an impaired PFS, translat-
ing into a trend towards an unfavorable OS [22].
In conclusion, there was no association between the use of
vemurafenib in a reduced dose or the simultaneous use of
vemurafenib andARAs and the risk of progression. In addition,
there was no increased risk of progression among patients who
used reduced-dose vemurafenib and ARAs. However, patients
using full-dose vemurafenib simultaneously with ARAs might
have an increased risk of progression. This finding requires
prospective validation. Moreover, future studies are necessary
to investigate the added value of measuring vemurafenib con-
centrations in order to optimize therapy.
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